By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines
Stocks

Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines

News Room
Last updated: 2023/05/28 at 3:47 AM
By News Room
Share
3 Min Read
SHARE
2/2

© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron

2/2

By Blake Brittain

(Reuters) – Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc (NYSE:) and Moderna (NASDAQ:) Inc in Delaware federal court, again claiming that the companies’ COVID-19 vaccines infringe its patents.

The new lawsuits mark the third time Alnylam has sued Pfizer and Moderna in Delaware for allegedly violating its patent rights in lipid nanoparticle (LNP) technology, which the vaccines use to deliver genetic material into the body.

Alnylam is again seeking an unspecified share of royalties from the companies’ vaccine sales. Pfizer earned $37.8 billion from sales of its COVID-19 vaccine Comirnaty last year, while Moderna made $18.4 billion from its vaccine Spikevax.

Representatives for Alnylam, Moderna and Pfizer did not immediately respond to requests for comment on the new lawsuits. Moderna and Pfizer have denied the allegations in the earlier cases and argued that Alnylam’s patents are invalid.

Cambridge, Massachusetts-based Alnylam first sued Moderna and Pfizer last March. It filed another pair of complaints last July over an additional LNP patent, which were later consolidated with its earlier lawsuits.

The lawsuits filed Friday include four new infringement claims against Pfizer and three against Moderna.

The complaints are part of a wave of patent lawsuits filed by biotech companies over COVID-19 vaccines, including a case brought by Moderna against Pfizer last year in Massachusetts.

Alnylam told the Delaware court that it pioneered LNP technology “essential” to the mRNA-based vaccines more than a decade ago. It also said it gave Moderna confidential information about the technology in 2014 during discussions about a potential collaboration.

The cases are Alnylam Pharmaceuticals Inc v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00580 and Alnylam Pharmaceuticals Inc v. Pfizer Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00578.

For Alnylam: William Gaede, Sarah Columbia, Sarah Fischer, Ian Brooks and Bhanu Sadasivan of McDermott Will & Emery

For Moderna and Pfizer: attorney information not available

Read more:

Alnylam files patent infringement lawsuits against Pfizer, Moderna

Pfizer, Moderna COVID-19 vaccines infringe new Alnylam patent, lawsuits say

Pfizer says COVID-19 vaccine lawsuit is based on bogus patent

Read the full article here

News Room May 28, 2023 May 28, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Tesla bull Dan Ives talks why he’s still bullish, AT&T COO talks wireless competition

Watch full video on YouTube

Why The U.S. Is Running Out Of Explosives

Watch full video on YouTube

REX American Resources Corporation 2026 Q3 – Results – Earnings Call Presentation (NYSE:REX) 2025-12-05

This article was written byFollowSeeking Alpha's transcripts team is responsible for the…

AI won’t take your job – but someone using it will

Watch full video on YouTube

Could Crypto-Backed Mortgages Put The U.S. Housing Market At Risk?

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?